Showing 7751-7760 of 8648 results for "".
- Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for Eysuvishttps://modernod.com/news/kala-pharmaceuticals-to-host-key-opinion-leader-symposium-on-unmet-need-in-dry-eye-disease-and-potential-for-eysuvis/2478270/Kala Pharmaceuticals announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for Eysuvis as a short-term treatment for the signs and symptoms of the disease. The event will be held virtually on Thursday, September 17, 2020, beginning at 8
- Clearside Biomedical’s Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjectorhttps://modernod.com/news/clearside-biomedicals-partner-doses-first-patient-in-its-phase-2-study-in-patients-with-choroidal-melanoma-using-scs-microinjector/2478269/Clearside Biomedical announced that its licensing partner, Aura Biosciences, has dosed the first patient in its phase 2 clinical trial evaluating the safety and efficacy of suprachoroidal administration of AU-011 as a potential first-line treatment for patients with primary choroi
- HelpMeSee Names Saro Jahani As President and CEOhttps://modernod.com/news/helpmesee-names-saro-jahani-as-president-and-ceo/2478266/Nonprofit HelpMeSee announced the appointment of Saro Jahani as President and CEO. He will also join the Board of Directors. Mr. Jahani succeeds Jacob Mohan Thazahathu, who retired after 10 years of service. Mr. Jahani
- BVI Expands Malosa Single-Use Instrument Range in the UShttps://modernod.com/news/bvi-expands-malosa-single-use-instrument-range-in-the-us/2478253/BVI announced the extension of its Malosa range of single-use ophthalmic instruments in the US. The US Malosa portfolio will now include specialty instruments for use in corneal refractive surgery, complementing the existing single-use product range for cataract, oculoplastic, and office-based pr
- Saliva COVID-19 Test as Good as, Perhaps Beats, Nasal Swab: Studyhttps://modernod.com/news/saliva-covid-19-test-as-good-as-perhaps-beats-nasal-swab-study/2478248/A COVID-19 saliva test protocol developed by researchers at Yale University appeared to perform at least as well as nasal swabs in a study of hospital patients, a finding that may help encourage more frequent use of self-collected samples, according to a Medscape
- LumiThera Receives $1.5 Million Grant From National Eye Institute to Support Trial for Treating Diabetic Retinopathy and Macular Edemahttps://modernod.com/news/lumithera-receives-1-5-million-grant-from-national-eye-institute-to-support-trial-for-treating-diabetic-retinopathy-and-macular-edema/2478242/LumiThera announced it is a recipient of a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI). The grant supports a prospective, randomized, multicenter human clinical trial in U.S. subjects diag
- Genentech to Present New Data in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder at MSVirtual2020https://modernod.com/news/genentech-to-present-new-data-in-multiple-sclerosis-and-neuromyelitis-optica-spectrum-disorder-at-msvirtual2020/2478238/Genentech announced that new multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) data will be presented at MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) – European Committee for Treatment and Research in Mul
- NIH Panel Finds “Insufficient” Data to Support Use of Plasma for COVID-19https://modernod.com/news/nih-panel-finds-insufficient-data-to-support-use-of-plasma-for-covid-19/2478235/A panel of the National Institutes of Health (NIH) concluded that “there are insufficient data to recommend either for or against the use of convalescent plasma for the treatment of COVID-19.” The review by the COVID-19 Treatment Guidelines Panel comes shortly after the FDA issued an
- Injectsense Receives Breakthrough Device Program Designation From FDA for IOP Monitoring Systemhttps://modernod.com/news/injectsense-receives-breakthrough-device-program-designation-from-fda-for-iop-monitoring-system/2478233/Injectsense announced it has received a breakthrough device program (BDP) designation from the FDA for its chronic continuous IOP monitoring system for glaucoma patients. The company’s IOP Connect system is based on a long-term implantable sensor, smaller than a grain of rice, that is delivered t
- Oxurion NV Reports First Patient Dosed in Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)https://modernod.com/news/oxurion-nv-reports-first-patient-dosed-in-phase-2-study-evaluating-thr-149-for-treatment-of-diabetic-macular-edema-dme/2478228/Oxurion NV reported that the first patient has been dosed in its two-part phase 2 study (“KALAHARI”) evaluating THR-149 for the treatment of DME. THR-149 acts through inhibition of the Plasma Kallikrein-Kinin (PKaI-Kinin) system, a validated VEGF independent target for DME. In a phase 1 st